Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab versus placebo as adjuvant therapy in ctDNA-positive high-risk muscle-invasive bladder cancer after cystectomy
2022-502705-15-00Phase 3Completed
- Sponsor
- Roche
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 24
01
Overview
Phase 3, randomised, double-blind trial in muscle-invasive bladder cancer (MIBC) and transitional cell carcinoma of the bladder (TCC) comparing Atezolizumab with Placebo (2 arms). Primary endpoint: Investigator-assessed disease-free survival. Started Mar 2021; status: completed.
02
Drugs
atezolizumab
03
Conditions
muscle-invasive bladder cancer (MIBC)transitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on 2022-502705-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502705-15-00.